2. Signalwege
  3. GPCR/G Protein
    MAPK/ERK Pathway
  4. Ras

Ras

Ras

Related Products

PDF 2.6 MB

Ras is the name given to a family of related proteins which is ubiquitously expressed in all cell lineages and organs. All Ras protein family members belong to a class of protein called small GTPase, and are involved in transmitting signals within cells. Ras is the prototypical member of the Ras superfamily of proteins, which are all related in 3D structure and regulate diverse cell behaviours. When Ras is 'switched on' by incoming signals, it subsequently switches on other proteins, which ultimately turn on genes involved in cell growth, differentiation and survival. As a result, mutations in ras genes can lead to the production of permanently activated Ras proteins. This can cause unintended and overactive signalling inside the cell, even in the absence of incoming signals. Because these signals result in cell growth and division, overactive Ras signaling can ultimately lead to cancer. The 3 Ras genes in humans (HRAS,KRAS, and NRAS) are the most common oncogenes in human cancer; Ras inhibitors are being studied as a treatment for cancer, and other diseases with Ras overexpression.

Ras Isoform Specific Products:

Ras Isoform Comparison
Art. -Nr. Produktname Wirkung Reinheit Chemical Structure
  • HY-162439
    pan-KRAS-IN-6
    		Inhibitor
    pan-KRAS-IN-6 (compound 12) is a potent pan KRAS inhibitor with IC50 values of 9.79 nM (Kras G12D) and 6.03 nM (Kras G12V).
    pan-KRAS-IN-6
  • HY-145018
    KRAS G12C inhibitor 21
    		Inhibitor
    KRAS G12C inhibitor 21 is a KRAS G12C inhibitor extracted from patent WO2021219090A1, example 7.
    KRAS G12C inhibitor 21
  • HY-143590
    KRAS G12C inhibitor 37
    		Inhibitor
    KRAS G12C inhibitor 37 is a potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12C inhibitor 37 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2018143315A1, compound 65).
    KRAS G12C inhibitor 37
  • HY-P991743
    Anti-KRAS Antibody
    Anti-KRAS Antibody is a human-derived IgG1 kappa monoclonal antibody against KRAS.
    Anti-KRAS Antibody
  • HY-176918
    K-Ras ligand-Linker Conjugate 8
    		Degrader
    K-Ras ligand-Linker Conjugate 8 is a Target Protein Ligand-Linker Conjugate that incorporates a ligand for KRAS (HY-162960) and a PROTAC linker, which recruits E3 ligases. K-Ras ligand-Linker Conjugate 8 can be used for synthesis of PROTAC KRAS(on) degrader ACBI-4 (HY-176792).
    K-Ras ligand-Linker Conjugate 8
  • HY-178497
    ZJK-807
    		Degrader
    ZJK-807 is a highly effective and selective PROTAC degrader targeting KRASG12D (DC50 = 79.5 nM in AsPC-1 cells). ZJK-807 shows minimal impact on wild-type KRAS or other mutants (G12C/S/V, G13D), inducing mutant-specific cytotoxicity. ZJK-807 suppresses RAS/MAPK signaling and uniquely modulates TNF signaling and eukaryotic ribosome biogenesis. ZJK-807 can be used for the study of KRAS-driven pancreatic cancer. Yellow: KRASG12D ligand (HY-W087383); Green: E3 ligase CRBN ligand (HY-178507); Black: Linker (HY-178506).
    ZJK-807
  • HY-181728
    MS243
    		Degrader
    MS243 is a potent KRASG12D PROTAC degrader with a DC50 of 4.2 nM. MS243 promotes the proximity between KRASG12D and the VHL E3 ubiquitin ligase, drives the ubiquitination and proteasomal degradation of KRASG12D, and inhibits the proliferation of cancer cells harboring KRASG12D. MS243 can be used in the research of KRASG12D-carrying cancers, such as colon cancer and pancreatic cancer.
    MS243
  • HY-173460
    RAS-IN-3
    		Inhibitor
    RAS-IN-3 (compound 22) is a potent Ras inhibitor. ROCK-IN-12 can be used in the study of Non-small cell lung cancer and colorectal cancer .
    RAS-IN-3
  • HY-179480
    G-quadruplex ligand 4
    		Inhibitor
    G-quadruplex ligand 4 is a chromenone derivative and is a human telomerase reverse transcriptase (hTERT) G4 ligand. G-quadruplex ligand 4 downregulates hTERT expression and exhibits notable cytotoxicity towards triple-negative breast cancer (TNBC) cell lines. G-quadruplex ligand 4 can cause S/G2 cell cycle arrest and induce apoptosis. G-quadruplex ligand 4 downregulates the expression of hTERT, KRAS, and BCL-2. G-quadruplex ligand 4 can be used for the research of TNBC.
    G-quadruplex ligand 4
  • HY-163489
    pan-KRAS-IN-15
    		Inhibitor
    pan-KRAS-IN-15 (compound 58) is a pan-KRAS inhibitor. pan-KRAS-IN-15 can be used in pancreatic cancer research.
    pan-KRAS-IN-15
  • HY-P2157
    Ras Inhibitory Peptide
    		Inhibitor
    Ras Inhibitory Peptide (VPPPVPPRRR) is a Ras inhibitor with antitumor activity.
    Ras Inhibitory Peptide
  • HY-172531
    Sulfonadyn-47
    		Inhibitor
    Sulfonadyn-47 is a GTP-competitive dynamin I (dynI) inhibitor that targets the active site in the GTPase domain of dynamin I, with IC50 values of 3.5 μM against dynI, 27.3 μM in clathrin-mediated endocytosis (CME) assays, and 12.3 μM in synaptic vesicle endocytosis (SVE) assays. Sulfonadyn-47 increases seizure threshold. Sulfonadyn-47 can be used the study for the seizure.
    Sulfonadyn-47
  • HY-153412
    KRAS inhibitor-22
    		Degrader
    KRAS inhibitor-22 (compound FB9/6B9) is a potent inhibitor of K-Ras. KRAS inhibitor-22 targets to Kras 4B(G12D) and (G12C), which can be used for cancer research.
    KRAS inhibitor-22
  • HY-153881
    KRAS G12C degrader-1
    KRAS G12C degrader-1 (Compound 283) is a potent KRAS G12C degrader (DC50: < 100 nM) for cancer research. KRAS G12C degrader-1 is a chaperone (HSP90)-mediated protein degrader (CHAMPs).
    KRAS G12C degrader-1
  • HY-146543
    KRAS inhibitor-13
    		Inhibitor
    KRAS inhibitor-13 (compound 5-6) is a potent KRAS G12C inhibitor with an IC50 of 0.883 µM. KRAS inhibitor-13 shows p-ERK inhibition activities with IC50s of 5.9, >100 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-13 has the potential for the research of pancreatic, colorectal, and lung cancers.
    KRAS inhibitor-13
  • HY-142946
    KRAS G12C inhibitor 44
    		Inhibitor
    KRAS G12C inhibitor 44 (compound 54) is a potent and orally active KRAS G12C inhibitor. KRAS G12C inhibitor 44 shows anti-proliferation activities with IC50s of 0.016, 0.028 µM in MIA PaCA-2, H358 cells, respectively. KRAS G12C inhibitor 44 shows antitumor effects in vivo.
    KRAS G12C inhibitor 44
  • HY-153989
    SOS1-IN-16
    		Inhibitor
    SOS1-IN-16 (Comp 54) is a selective inhibitor of SOS1 with an IC50 of 7.2 nM. SOS1-IN-16 has inhibitory activity of CYP3A4 when using testosterone as a substrate, with an IC50 of 8.9μM. SOS1-IN-16 can be used for cancer research.
    SOS1-IN-16
  • HY-147633
    KRAS G12C inhibitor 52
    		Inhibitor
    KRAS G12C inhibitor 52 (Compound 7) is a KRAS G12C inhibitor.
    KRAS G12C inhibitor 52
  • HY-146432
    Antitumor agent-60
    		Inhibitor
    Antitumor agent-60 (compound 20) is a potent antitumor agent, targeting RAS-RAF signaling pathway and binding to CRAF with a Kd value of 3.93 μM. Antitumor agent-60 induces apoptosis by blocking cell cycle at G2/M phase. Antitumor agent-60 enhances the level of p53 and ROS. Antitumor agent-60 causes oval and irregular nucleus in cancer cells. Antitumor agent-60 can suppress the growth of tumor to some extent in A549 xenograft model.
    Antitumor agent-60
  • HY-163880
    EGFR-IN-119
    		Inhibitor
    EGFR-IN-119 (Compound 5l) is an inhibitor for EGFR with an IC50 of 84.3 nM. EGFR-IN-119 inhibits the cytotoxicity in lung cancer cell A549 with an IC50 of 1.34 μM. EGFR-IN-119 downregulates the expressions of EGFR, KRAS, and MAP2K genes, exhibits antioxidant activity through reduction of reactive oxygen species (ROS), and hyperpolarizes the mitochondrial membrane potential.
    EGFR-IN-119
Art. -Nr. Produktname / Synonyms Application Reactivity
Ras Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.